Know Cancer

or
forgot password

Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only.


Phase 2
20 Years
N/A
Not Enrolling
Both
Esophageal Cancer

Thank you

Trial Information

Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only.


Inclusion Criteria:



- Patients must have measurable disease

- Patients must have experienced on pervious chemotherapy regime

- Men and Women, with the age 20 years or older

- ECOG PS: 0-1

Exclusion Criteria:

- Patients with previous therapy with Taxanes

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall response rate

Outcome Time Frame:

at the end of the study

Safety Issue:

No

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

Japan: Pharmaceuticals and Medical Devices Agency

Study ID:

CA139-540

NCT ID:

NCT00344552

Start Date:

June 2006

Completion Date:

March 2008

Related Keywords:

  • Esophageal Cancer
  • Esophageal Diseases
  • Esophageal Neoplasms

Name

Location